Tranzyme, Inc. (TZYM) Reports In-Line Q2 Loss of 23c/Share

Tranzyme, Inc. (NASDAQ: TZYM) reported Q2 EPS of ($0.23), in-line with the analyst estimate of ($0.23). Revenue for the quarter came in at $2.41 million versus the consensus estimate of $2.97 million.

For earnings history and earnings-related data on Tranzyme, Inc. (TZYM) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Is the global equity rally broadening? UBS weighs in
• BMO starts chip stocks coverage: Here are its preferred picks